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ABSTRACT
Objective: Toona sureni (Indonesian mahogany) is a member of Meliaceae family and locally known as suren. Previous study reported that T. sureni 
leaves extract exhibited antiviral activity with 50% inhibitory concentration (IC50) value of 13.9 ± 1.6 µg/ml against hepatitis C virus (HCV) J6/JFH1. 
Cytotoxicity analysis of T. sureni leaves extract did not reveal any cytotoxicity effect; therefore, further study was taken to investigate the active 
substances from the extract.
Methods: Bioassay-guided isolation of anti-HCV was conducted using Huh-7.5 cells infected with HCV J6/JFH1 in the presence of extracts, fractions, 
or compounds from the plant.
Results: Ethyl acetate fraction (Fr E) exhibited high anti-HCV activity with IC50 value of 1.7 µg/ml. Further, separation of Fr E by open column 
chromatography resulted in nine sub-fractions (sub-Fr E1-E9). Sub-Fr E3 and E4 have IC50 value of 29.90 µg/ml and 7.68 µg/ml, respectively. 
Polyphenols compounds have been isolated from sub-Fr E3 and E4. The structures have been determined to be ethyl gallate (1), methyl gallate (2), 
catechin (3), gallic acid (4), and quercetin 3-O-rhamnoside (5). Among the isolated compounds, gallic acid showed to possess strong anti-HCV activity 
with IC50 value of 15.9 µg/ml.
Conclusion: T. sureni and its isolated compound, gallic acid, may be good candidates to develop for alternative and/or complementary agents of 
anti-HCV infection.
Keywords: Toona sureni, Leaves extract, Polyphenols, Antihepatitis C virus, Gallic acid.
INTRODUCTION
Hepatitis C virus (HCV) is a major cause of liver disease and potential 
cause of substantial morbidity and mortality worldwide. Global 
prevention and control of HCV were met with difficulties due to the 
complexity and uncertainty related to the geographic distribution of 
HCV infection and chronic hepatitis C, determination of its associated 
risk factors, and evaluation of cofactors that accelerate its progression. 
No vaccine is available to prevent HCV infection, nor does immune 
globulin provide protection [1,2].
Hepatitis C is an RNA virus that mutates very rapidly, until now, there 
were seven genotypes (1–7) with more than 70 subtypes. HCV genome 
encodes structural protein (Core, E1, and E2) and non-structural 
protein (NS2, NS3, NS4A, NS4B, NS5A, and NS5B). Glycoproteins E1 
and E2 were responsible for virus binding to the cell surface meanwhile 
the function of non-structural protein was RNA replication and virus 
particle construction [3-5]. The current standard interferon-free 
treatment regimens with a combination of direct-acting antiviral agents 
(DAAs) targeting the viral NS3 protease, NS5A multifunction protein, 
and NS5B RNA-dependent RNA polymerase result sustained virological 
responses >90%. However, the emergence of DAA-resistant HCV strains, 
limited access to the DAAs due to their high cost is also an important 
issue. Many therapies for HCV infection have been developed, but the 
therapeutic efficacy still needs to be improved [6]. In future, anti-HCV 
research should aim at the development of therapies for non-responder 
patient population and treatment regiments with short duration of 
treatment [7].
Many plants species are being tested for anti-HCV to find a possible 
cure for HCV. Some of them have shown significant inhibition in entry, 
replication, and assembly steps of the viral life cycle [8]. Moreover, 
some compounds have been isolated and tested for anti-HCV. Previous 
study reported that chalepin and pseudane IX which isolated from 
Ruta angustifolia leaves showed strong anti-HCV activities with 50% 
inhibitory concentration (IC50) value of 1.7 ± 0.5 and 1.4 ± 0.2 µg/ml, 
respectively, without apparent cytotoxicity [9]. A major catabolite of 
chlorophyll A, which was isolated from Morinda citrifolia and identified 
as pheophorbide A, was reported to possess anti-HCV activity with 
IC50 value of 0.3 µg/ml. It was reported also that pyropheophorbide 
A is an anti-HCV compound with IC50 value of 0.2 µg/ml [10]. Adianti 
et al. suggested that glycycoumarin, glycerin, glycerol, and liquiritigenin 
isolated from Glycyrrhiza uralensis, as well as isoliquiritigenin, 
licochalcone A, and glabridin, would be good candidates for seed 
compounds to develop antivirals against HCV [11]. Quercetin and 
gallic acid isolated from Kalanchoe pinnata inhibited HCV production 
in a dose-dependent manner with IC50 value of 1.5 and 6.1 µg/ml, 
respectively, without exhibiting cytotoxicity [12].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Evaluation of certain Indonesia medicinal plants explored from East 
Java revealed that Toona sureni is one of the good candidates for the 
development of anti-HCV drugs. T. sureni (Indonesian mahogany) is 
a member of Meliaceae family and locally known as suren. The study 
reported that ethanol extract of T. sureni leaves exhibited antiviral 
activity with IC50 value of 13.9 ± 1.6 µg/ml against HCV J6/JFH1. Time of 
addition experiment revealed that the extract inhibited both at the entry 
and postentry steps. T. sureni leaves extract was not toxic (cytotoxicity 
concentration [CC50]>500 µg/ml, SI>35.9); therefore, further study 
was taken to investigate the active substances from T. sureni leaves 
extract [13].
Another Toona species has been known for other activity. T. sinensis 
has activity for antimicrobial, anticancer, anti-inflammation, radical 
scavenging, and antioxidant in the liver. T. ciliata and T. pubescens have 
been used traditionally as a treatment for diarrhea, as cardiotonic, 
astringent, and antioxidant [8,14-18]. However, Jain et al. reported in 
his research that the antioxidant activity level can affect reduction of 
chronic hepatitis and cirrhosis [19].
METHODS
Plant material
T. sureni leaves were collected from Pujon, East Java, Indonesia. 
Authentication and identification of plant were carried out at the 
Purwodadi Botanical Garden, East Java.
Extraction and isolation
Leaves of T. sureni were dried at room temperature and pulverized. Dried 
leaves powder (250 g) were extracted using 80% ethanol by maceration 
method. The ethanol extract was filtered and concentrated using rotary 
evaporator. The crude ethanol extract (25.6 g) was suspended in 
water and partitioned between chloroform, ethyl acetate, and butanol, 
successively to obtain chloroform, ethyl acetate, butanol, and water 
fraction, respectively. Ethyl acetate fraction (8.63 g) was further separated 
on silica gel column using chloroform-methanol 5% gradient system 
resulted in nine sub-fractions (Sub-Fr E1–E9). Sub-Fr E3 was subjected 
to open column chromatography using silica gel and chloroform-ethyl 
acetate (1:1) to yield ethyl gallate (1). Sub-Fr E4 was further subjected 
to silica gel column (chloroform/methanol 90:1-50:50) resulted in 
nine sub-fractions (Sub-Fr E4.1–E4.9). Sub-Fr E4.1 further subjected 
to silica gel column (hexane/ethyl acetate 40:60; 20:80, ethyl acetate, 
and methanol) to yield ethyl gallate (1). Sub-Fr E4.2 was subjected to 
semi-preparative high-performance liquid chromatography (HPLC) 
system (C-18 column, 5 um, 10×250 mm, flow rate 2.5 ml/min) using 
acetonitrile-water (20–80%) to yield methyl gallate (2). Sub-Fr E4.3 
was also subjected to semi-preparative HPLC using the same condition 
(flow rate 1.5 ml/min) to obtain gallic acid (3) and catechin (4). Sub-
Fr E4.4 was also subjected to semi-preparative HPLC using the same 
condition (flow rate 1.5 ml/min) to yield quercetin 3-O-rhamnoside 
(5). Structure elucidation based on nuclear magnetic resonance (NMR) 
data dan references data. The1H NMR spectra were measured with 
JEOL ECA 500 spectrometer (500 MHz), while HPLC was performed on 
Shimadzu system.
Cells and viruses
Huh-7.5 cells were cultivated in Dulbecco’s modified Eagle’s medium 
supplemented with fetal bovine serum, non-essential amino acids, 
penicillin, and streptomycin. Cells were grown at 37°C in a 5% CO2 
incubator.
Analysis of anti-HCV activities
T. sureni extract and fractions were dissolved in dimethyl sulfoxide 
(DMSO) to obtain stock solutions at a concentration of 100 mg/ml. The 
stock solutions were stored at −20°C until they were used. Analysis 
of anti-HCV method was described previously [9,13]. Huh-7.5 cells 
were seeded in 24-well plates (cell density 1.9×105 cells/well). A fixed 
amount of J6/JFH1 with multiplication of infection of 0.5 focus-forming 
units/cell was mixed with serial dilutions of the extracts (100, 30, 
10, 1, and 0.1 µg/ml) and inoculated to the cells. After 2 h, the cells 
were washed with medium to remove the residual virus and further 
incubated in the medium containing the same concentrations of the test 
samples as those during virus inoculation.
Culture supernatants were obtained at 2-day postinfection and titrated 
for virus infectivity. Virus and cells treated with medium containing 
0.1% DMSO served as a control. The inhibition percentage of virus 
infectivity by the samples was calculated by comparing to the control 
using SPSS probit analysis, and the IC50 value was determined.
Cytotoxicity assay
The cytotoxicity of the samples was assessed by WST-1 assay. Huh-
7.5 cells were seeded in 96-well plates and treated with serial dilution 
of the samples or control (0.1% DMSO) for 48 h. The condition of 
cells was observed under microscope to detect the toxic effect on cell 
morphology. After 48 h, the medium was removed from 96-well plates 
and then added with 10% of WST-1 reagent (10 µl/well) and incubated 
for 4 h at 37°C. The absorbance of samples was measured at 560 nm 
and 750 nm. Cell viability percentage and 50% CC50 were calculated.
RESULTS AND DISCUSSION
Bioactivity-guided isolation of anti-HCV compounds from T. sureni 
was conducted using Huh-7.5 cells infected with HCV J6/JFH1 in the 
presence of extract, fractions, or compounds from the plant. To isolate 
an active substance(s) responsible for the anti-HCV activity, the crude 
ethanol extract was partitioned into chloroform (Fr C), ethyl acetate 
(Fr E), butanol (Fr B), and water fractions (Fr W), and their anti-HCV 
activities were evaluated. The result showed that the Fr C and Fr E 
had strong anti-HCV activities with IC50 values of 1.6 and 1.7 µg/ml, 
respectively (Table 1).
Due to the anti-HCV activities of Fr E, further separation of Fr E was 
done by open column chromatography and resulted in nine sub-
fractions (Sub-Fr E1-E9). These fractions were evaluated for anti-HCV 
and cytotoxic activities. The result obtained revealed that sub-Fr E3 
and E4 have strong anti-HCV activities with IC50 value of 29.9 µg/ml and 
7.7 µg/ml, respectively (Table 2).
Sub-Fr E3 and E4 were subjected to further purification which yielded 
some polyphenols compounds that have been determined to be 
ethyl gallate (1), methyl gallate (2), catechin (3), gallic acid (4), and 
quercetin 3-O-rhamnoside (5) (Fig. 1). Chemical structures of isolated 
compounds were elucidated based on NMR spectroscopy and reference 




Chloroform fraction (Fr C) 1.6
Ethyl acetate fraction (Fr E) 1.7
Butanol fraction (Fr B) 15.4
Water fraction (Fr W) 50.0
T. sureni: Toona sureni, IC50: 50% inhibitory concentration











*NT: Not tested. T. sureni: Toona sureni, IC50: 50% inhibitory concentration
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data. Anti-HCV activities of those compounds were then evaluated. The 
results showed that gallic acid mediates a strong anti-HCV activity with 
IC50 value of 15.90 µg/ml, while ethyl gallate and catechin revealed 
moderate activities with IC50 value of 52.5 and 52.0 µg/ml, respectively. 
On the other hand, the presence of methyl moiety in the methyl gallate 
resulting inactive compound against HCV, suggesting that moiety of 
OH in gallic acid may play an important role for its anti-HCV activities 
(Table 3).
Gallic acid is also a common natural constituent of a variety of plants. In 
the present study, gallic acid was identified as a compound with stronger 
anti-HCV activity than the other isolated compounds. According to 
Hsu et al. reported that gallic acid inhibits HCV in the entry step. This 
compound inactivates cell-free viral particle and blocks its attachment 
to the host cells. However, it has a little effect on postbinding of viral 
entry and fusion stage [20]. Gallic acid is also known to have antioxidant 
and hepatoprotective activities [21,22]. Most phenolic compounds have 
radical-scavenging activity. The activity depends on the number and 
position of hydroxyl group substituent in the molecules as which called 
on the antioxidant activity of flavonoids is known to be associated 
with the number of free hydroxyl groups [23]. Jain et al. also reported 
in his research that the antioxidant activity level can affect reduction 
of chronic hepatitis and cirrhosis [19]. It is conceivable, therefore, 
that the anti-HCV mechanism of gallic acid involves its antioxidant 
activities. Other researchers reported that polyphenols like gallic 
acid were responsible for the anti-HCV activity in plants [24]. Recent 
study showed that gallic acid decreases the HCV expression through its 
antioxidant activities. Gallic acid reduced the level of reactive oxygen 
species generated by strong oxidizing agent, such as H2O2, which could 
inhibit viral replication. This compound attenuates the translation 
rate of viral proteins or decreases the stability of viral protein [25]. 
Moreover, gallic acid was reported to inhibit several other viruses such 
as influenza virus, foodborne viral surrogates, murine norovirus-1, and 
feline calicivirus-F9 [26,27]. The antiviral activities of gallic acid might 
be caused by the hydrophobic interaction between the functional group 
(hydroxyl) and virion components, bind to free radicals and exert an 
antioxidant effect [25].
CONCLUSION
Plant of T. sureni is a potential source for anti-HCV agent. Ethyl acetate 
fraction (Fr E) of this plant is active as anti-HCV against J6/JFH1 with 
IC50 value of 1.7 µg/ml. Ethyl gallate (1), methyl gallate (2), catechin (3), 
gallic acid (4), and quercetin 3-O-rhamnoside (5) were isolated from 
Fr E. Among the isolated compounds; gallic acid showed to possess 
strong anti-HCV activity with IC50 value of 15.9 µg/ml. These results 
suggested that T. sureni and its isolated compound, gallic acid, may 
be good candidates to develop for alternative and/or complementary 
agents of anti-HCV infection.
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